• AZD0156: A Pharmacology-First ATM Assay Guide

  2026-09-21

  AZD0156 is a selective ATM kinase inhibitor for dissecting DNA damage signaling and therapeutic sensitization. This pharmacology-first guide applies lessons from systematic kinase-inhibitor research to improve assay design, interpretation, and translational cancer therapy research.

• HHV-7 DNA in Ocular Toxoplasmosis: Study Insights

  2026-09-21

  This case report describes the first reported detection of human herpesvirus 7 DNA in vitreous humor from an eye with recurrent ocular toxoplasmosis, with simultaneous detection of Toxoplasma gondii DNA. The findings suggest that HHV-7 reactivation may contribute to refractory uveitis, while also illustrating why intraocular sampling and multiplex PCR can refine diagnosis when standard treatment fails.

• Ferroptosis Signatures and Atorvastatin in HCC

  2026-09-20

  Wang and colleagues combined ferroptosis-related transcriptomics, survival modeling, and Connectivity Map screening to develop a four-gene prognostic signature for hepatocellular carcinoma (HCC) and identify Atorvastatin as a candidate therapeutic compound. Cell and animal experiments further associated Atorvastatin exposure with ferroptosis, reduced HCC growth, and impaired migration, while also highlighting the need for disease-specific validation.

• LNP Surface Charge and V-ATPase Drive Delivery

  2026-09-19

  This study proposes that LNP tropism is determined by a functional match between nanoparticle surface charge and V-ATPase activity in the target cell or organ. Its combined in vitro, in vivo, perturbation, and protein-corona analyses provide a mechanistic framework for interpreting why differently charged LNPs favor distinct delivery sites.

• Bleomycin Sulfate A8331: Protocol & QC Guide

  2026-09-18

  Bleomycin Sulfate (SKU A8331) provides a practical DNA strand break-induction tool for cell-based damage assays and bleomycin-associated pulmonary fibrosis research. It is suitable for controlled in vitro and in vivo model development, but its ethanol insolubility, solution-storage limitations, cell-dependent potency, and model-specific inflammatory effects require explicit formulation and QC controls.

• Meropenem in Carbapenem Resistance Research

  2026-09-18

  Meropenem supports reproducible susceptibility testing, resistance-phenotype profiling, and infection-model design across Gram-negative and Gram-positive systems. This guide translates recent carbapenemase-transmission findings into practical assay choices, controls, and troubleshooting steps without treating research data as clinical guidance.

• Brain-to-Spinal Control of Opioid Pain Hypersensitivity

  2026-09-17

  Yin et al. identify a brain-to-spinal µ-opioid pathway that links lateral parabrachial MOR neurons, hypothalamic dynorphin neurons, and spinal dorsal-horn KOR-GABA neurons to morphine-induced mechanical hypersensitivity and analgesic tolerance. The study shows that focal MOR activation can produce a paradoxical mechanical pain phenotype and provides a circuit framework for interpreting opioid receptor signaling in chronic pain research.

• LNP Charge and V-ATPase Shape Nucleic Acid Delivery

  2026-09-17

  The reference study identifies a synergistic relationship between LNP surface charge and the V-ATPase activity of recipient cells, linking vector properties with target-cell endo/lysosomal state. Its findings suggest that delivery optimization should evaluate both nanoparticle design and cellular physiology rather than treating organ tropism as a property determined by the LNP alone.

• ML385: Practical NRF2 Inhibition Workflows

  2026-09-16

  ML385 enables controlled pharmacological suppression of NRF2 for cancer therapeutic resistance, oxidative stress, and pathway-dependency studies. This practical guide connects dose-response design with orthogonal validation and extends the workflow to the NRF2-dependent osteoclast findings reported in the reference study.

• Malic-Acid LNPs Deliver Uricase circRNA in Mice

  2026-09-16

  This 2026 Nature Communications study develops malic-acid-derived lipid nanoparticles that deliver secretory uricase circRNA and combine antioxidant activity with low immunogenicity. In male mouse models, the selected LMA2-C10 formulation produced sustained urate lowering while reducing inflammation, fibrosis, arthritic pain, and renal injury, although translation beyond these preclinical models remains uncertain.

• GKT137831 for Nox1/Nox4 Redox Workflows

  2026-09-15

  GKT137831 enables pathway-proximal testing of Nox1/Nox4-driven oxidative stress across pulmonary vascular, fibrotic, and metabolic disease models. This guide combines concentration planning, orthogonal ROS readouts, membrane-injury assays, and troubleshooting strategies to distinguish upstream redox control from late ferroptosis events.

• EZ Cap Cy5 Firefly Luciferase mRNA: Readout Logic

  2026-09-15

  EZ Cap Cy5 Firefly Luciferase mRNA enables researchers to distinguish mRNA delivery from productive translation using complementary fluorescence and bioluminescence signals. This article presents a mechanistic framework for assay design, carrier comparison, and translational interpretation beyond conventional dual-reporter workflows.

• Indomethacin Workflows for AKI Inflammation Research

  2026-09-14

  Indomethacin provides a practical COX-centered perturbation tool for separating prostaglandin-linked inflammation from the FXR–KLF11–JAK2/STAT3 mechanism reported in contrast-induced acute kidney injury. This guide translates the reference findings into cell-based assay design while extending the compound’s use to lipid metabolism study and membrane signaling modulation.

• Tauroursodeoxycholic Acid: ER Stress Workflows

  2026-09-14

  Tauroursodeoxycholic Acid, or TUDCA, is a practical chemical-chaperone tool for separating ER stress, mitochondrial injury, apoptosis, and autophagy in disease models. This guide translates ER stress findings from subarachnoid hemorrhage research into controlled cell-based workflows, assay choices, and troubleshooting strategies.

• Separating Growth Arrest from Cell Death in Cancer Assays

  2026-09-13

  Schwartz’s dissertation distinguishes relative viability from fractional viability, showing why a single in vitro endpoint can obscure whether a cancer drug primarily slows proliferation, induces cell death, or does both. Its timing- and response-oriented framework supports more rigorous interpretation of checkpoint-directed therapies and drug combinations.

7799 records 1/520 page Next 12345 下5页 Last page